15F-12B - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

EFFECT - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

S-8 POS - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

S-8 POS - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

S-8 POS - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

S-8 POS - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

S-8 POS - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

POS AM - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

25 - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scalePHAXIAM phages demonstrated outstanding performance against clinical bacterial strains Lyon (France) – November 18, 2024, at 06:00 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), hereafter "The Company" or PHAXIAM, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented th

Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company's voluntary delisting of American Depositary Shares ("ADSs") representing its ordinary shares from The Nasdaq Capital Market ("Nasdaq") has become effective. Each ADS represents one ordinary share of the Company. The Company will file a Form 15 with the Securities and Exchange Commission ("SEC") to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in respect of the ADSs and

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq delisting will significantly reduce PHAXIAM's cash utilization and enable the Company to focus its financial resources on key development and value milestones Lyon (France) and Cambridge (MA, US), February 20, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced it has given formal notice to the Nasdaq Stock Market of the Company's intention to voluntary d

Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024. Cash position as of December 31, 2023 As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million). With the implementation of additional cost-cutting measures, PHAXIAM Therapeutics estimates that its current cash position will enable the Company to finance its current programs and expected operating

Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in high-value indicationsEarly access program continues to gain momentum with the treatment of more than 90 patients suffering from severe and resistant infection prosthetic joint infections of the hip or knee (PJI) Cash and cash equivalents of €15.6 million ($16.5 million) as of September 30, 2023 Lyon (France) et Cambridge (MA, US), November 14, 2023, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant b

Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, announces the approval of its phase 1 study clinical design in endocarditis infections caused by Staphylococcus aureus (S. aureus) by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the South-East II-Lyon Ethics Committee (Comité de Protection des Personnes - CPP

Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares. In its initiation study entitled "Ambition de leadership mondial de la phagothérapie - Ambition for global leadership in phage therapy" (only available in French), TP ICAP Midcap began covering the stock with a "Buy" recommendation and valued the Company at €8.5 per share1. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutic

Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024. Cash position as of December 31, 2023 As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million). With the implementation of additional cost-cutting measures, PHAXIAM Therapeutics estimates that its current cash position will enable the Company to finance its current programs and expected operating

Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in high-value indicationsEarly access program continues to gain momentum with the treatment of more than 90 patients suffering from severe and resistant infection prosthetic joint infections of the hip or knee (PJI) Cash and cash equivalents of €15.6 million ($16.5 million) as of September 30, 2023 Lyon (France) et Cambridge (MA, US), November 14, 2023, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant b